Clinical trials: Disorders of the Autonomic Nervous System
Multiple System Atrophy
A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy
This is a Phase 2, double-blind, placebo-controlled, multi-center, Phase II, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and efficacy of Ya-101 in subjects with multiple system atrophy.
- Trial name
- NCT06848231
- Testing
- YA-101
- Where
- 9 sites in United States, Japan and 1 more
- Volunteers
- 75 people
- Sponsor
- Dasher Neuroscience Inc.
Episodic Cluster Headache
Civamide Nasal Solution for Cluster Headache
The purpose of this study is to evaluate the safety and efficacy of intranasally administered civamide nasal solution in the prevention of cluster headaches during an episodic cluster headache period.
- Trial name
- ECH (NCT01341548)
- Testing
- Civamide nasal solution 0.01%
- Volunteers
- 180 people
- Sponsor
- Winston Laboratories
Cluster Headache - Episodic and Chronic
Safety and Efficacy Study of SOM230 s.c. in Cluster Headache
The purpose of this study was to determine if SOM230 is safe and effective for the treament of cluster headache.
- Trial name
- NCT02619617
- Testing
- SOM230
- Where
- 4 sites in United States, Germany and 1 more
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Multiple System Atrophy, MSA - Multiple System Atrophy
Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for Treatment of Early to Moderate Stage Multiple System Atrophy (MSA)
Purpose of this phase 1 study is to assess the safety of intrathecal administration of allogeneic human oral mucosa stem cells (hOMSCs) in patients suffering from early to moderate stage Multiple System Atrophy (MSA)
- Trial name
- NCT05698017
- Testing
- hOMSC300
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Cytora Ltd.
Symptomatic Neurogenic Orthostatic Hypotension
Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
A Phase 3 study to evaluate efficacy, safety, and tolerability of ampreloxetine (TD-9855) in subjects with primary autonomic failures (MSA, PD, or PAF) and symptomatic nOH with up to 4 weeks of treatment.
- Trial name
- SEQUOIA (NCT03750552)
- Testing
- ampreloxetine
- Where
- 125 sites in United States, Australia and 17 more
- Volunteers
- 195 people
- Sponsor
- Theravance Biopharma
Syncope, Syncope, Vasovagal
Head-up Tilt Test in Patients With Reflex Syncope and Asystolic Response Who Received a Dual-chamber Pacemaker With the Closed Loop Stimulation (CLS) and Participated in the BIOSync Trial
The purpose of this study is to explore changes in patients' hemodynamic parameters during the Head-Up Tilt Test ("HUTT") and their timing with respect to onset of the Closed Loop Stimulation (CLS) pacing.
- Trial name
- BIO|Sync-HUTT (NCT06038708)
- Where
- 2 sites in Italy
- Volunteers
- 20 people
- Sponsor
- Biotronik SE & Co. KG
Orthostatic Hypotension, Reflex Syncope
Fainting Detection And Early Warning In Syncope Evaluation Study (ARISE)
To characterize the impact of orthostatic hypotension (OH) and Vasovagal syncope on signals measured using a wearable Holter monitor in the clinic and ambulatory setting.
- Trial name
- ARISE (NCT07502599)
- Testing
- Wearable holter monitor
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Boston Scientific Corporation
Multiple System Atrophy (MSA), Parkinson's Disease (PD)
A Study to Evaluate Satety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With PD and Patients With MSA
The non-randomized, open-label phase I study aims to evaluate the safety, tolerability, biodistribution, radiation dosimetry, and pharmacokinetics of SST001 in healthy volunteers, patients with MSA and patients with PD.
- Trial name
- NCT07604116
- Testing
- SST001
- Where
- 2 sites in China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Synusight Biotech (Shanghai) Co., Ltd.
Mitochondrial Diseases, Myalgic Encephalomyelitis Chronic Fatigue Syndrome
The Precision Mito- Mito Map COMPASS Study
Mito Map is a research tool that produces an Energy Score from information provided by a participant. This remote observational study has an initial enrollment target of 400 adults across seven prespecified cohorts: healthy…
- Conditions
- Mitochondrial Diseases, Myalgic Encephalomyelitis Chronic Fatigue Syndrome, Post-COVID-19 Condition, Postural Orthostatic Tachycardia Syndrome
- Trial name
- COMPASS (NCT07856121)
- Testing
- Mito Map Energy Score and Home Functional Assessments
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- AI Agent Vault, Inc. d/b/a Precision Mito
Osteoarthritis, Rheumatoid Arthritis
Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216)
The purpose of this study is to evaluate the safety of long-term treatment with HZT-501.
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Chronic Low Back Pain, Chronic Regional Pain Syndrome
- Trial name
- HZ-CA-304 (NCT00613106)
- Testing
- HZT-501, Ibuprofen
- Where
- United States
- Volunteers
- 179 people
- Sponsor
- Amgen
Chronic Fatigue Syndrome, Orthostatic Hypotension
Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome
A subset of patients suffering from chronic fatigue syndrome exhibit symptoms of neurally mediated hypotension. While the underlying pathophysiology of chronic fatigue syndrome is not precisely understood, a dysfunction of the…
- Conditions
- Chronic Fatigue Syndrome, Orthostatic Hypotension, Neurally Mediated Hypotension, Neurogenic Orthostatic Hypotension
- Trial name
- CFS201 (NCT00977171)
- Testing
- Droxidopa
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Chelsea Therapeutics
Advanced Solid Tumor
Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208)
The study was conducted in two periods, Period 1 (mass balance) and Period 2 (extension). The purpose of Period 1 of this study was to provide a quantitative characterization of the mass balance, rates and routes of elimination…
- Trial name
- NCT05246111
- Testing
- [14C]Berzosertib, Berzosertib, Topotecan
- Where
- 2 sites in Hungary
- Volunteers
- 6 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Multiple System Atrophy
Study of BHV-3241 in Participants With Multiple System Atrophy
The purpose of this study is to compare the efficacy of verdiperstat (BHV-3241) versus placebo in participants with Multiple System Atrophy
- Trial name
- M-STAR (NCT03952806)
- Testing
- Verdiperstat
- Where
- 48 sites in United States, Austria and 4 more
- Volunteers
- 421 people
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Cluster Headache, Episodic
Eptinezumab in Participants With Episodic Cluster Headache
The purpose of this study is to evaluate the efficacy of eptinezumab in participants with episodic Cluster Headache (eCH)
- Trial name
- ALLEVIATE (NCT04688775)
- Testing
- Eptinezumab
- Where
- 120 sites in United States, Belgium and 17 more
- Volunteers
- 231 people
- Sponsor
- H. Lundbeck A/S
Endometriosis
A Clinical Study To Investigate The Effectiveness And Safety Of Tanezumab In Treating Pain Associated With Endometriosis
The purpose of this study is to determine whether tanezumab is effective and safe in the treatment of pain associated with endometriosis.
- Trial name
- NCT00784693
- Testing
- Tanezumab
- Where
- 30 sites in United States
- Volunteers
- 48 people
- Sponsor
- Pfizer
Complex Regional Pain Syndrome Type I
Phase 3, Open-Label Extension Study of AMBTX-01 (Neridronate) for Complex Regional Pain Syndrome Type 1
A Phase 3 open-label extension study of AMBTX-01 (neridronate) for Complex Regional Pain Syndrome Type 1
- Trial name
- NCT07857733
- Testing
- Neridronate
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- Ambros Therapeutics, Inc.
Multiple System Atrophy
Observational Study in Multiple System Atrophy
Talisman is global clinical study (20058N) in Multiple System Atrophy (MSA) patients. It will be conducted in two regions (China and the European Union [EU]).
- Trial name
- TALISMAN (NCT05453058)
- Testing
- plasma NfL and brain MRI (vMRI, DTI, and ASL [if feasible]) only for the EU cohort
- Where
- 8 sites in China
- Volunteers
- 90 people
- Sponsor
- H. Lundbeck A/S
Chronic Cluster Headache
Pathway CH-1 Long-Term Follow-Up
The objective of the study is to demonstrate the long-term safety and performance of the ATI Neurostimulation System when used for stimulation of the sphenopalatine ganglion (SPG) in cluster headache subjects.
- Trial name
- NCT01616511
- Where
- 3 sites in Belgium, Denmark and 1 more
- Volunteers
- 33 people
- Sponsor
- Autonomic Technologies, Inc.
Multiple System Atrophy (MSA)
Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)
The purpose of this expanded access program is to provide access to the investigational drug verdiperstat in patients with Multiple System Atrophy (MSA).
- Trial name
- NCT05086094
- Testing
- BHV3241, verdiperstat
- Where
- United States
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Non-Small Cell Lung Cancer
Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)
This is an Open-label, multicenter clinical study conducted in two Phases to establish the efficacy, safety, tolerability, and pharmacokinetics of the ataxia telangiectasia mutated and Rad3-related protein kinase (ATR) inhibitor…
- Trial name
- NCT05882734
- Testing
- M1774, Cemiplimab
- Where
- 54 sites in United States, Belgium and 6 more
- Volunteers
- 61 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.